BRIEF published on 04/09/2024 at 09:11, 7 months 12 days ago Singulus Technologies AG: Mixed FY23 Results with Optimistic FY24 Outlook Investment Recommendation Singulus Technologies AG FY23 Results FY24 Outlook Solar Segment
PRESS RELEASE published on 04/09/2024 at 09:06, 7 months 12 days ago Original-Research: Singulus Technologies AG (von NuWays AG): Halten Singulus Technologies AG reported uninspiring FY23 results but anticipates sales and EBIT growth for FY24. The company aims for €120-130m in sales with a Hold recommendation and a target price of €1.60 Sales Growth HOLD Recommendation Singulus Technologies AG FY23 Results EBIT Growth
BRIEF published on 04/08/2024 at 08:15, 7 months 13 days ago SINGULUS TECHNOLOGIES Foresees Revenue and EBIT Growth in 2024 Semiconductor Industry Revenue Forecast Annual Financial Statements SINGULUS TECHNOLOGIES Solar Segment Growth
PRESS RELEASE published on 04/08/2024 at 08:10, 7 months 13 days ago SINGULUS TECHNOLOGIES publishes annual financial statements 2023 SINGULUS TECHNOLOGIES publishes annual financial statements for 2023 and expects revenue and EBIT growth in 2024. Positive developments in solar segment and semiconductor projects Revenue Growth Semiconductor Industry Annual Financial Statements EBIT Growth SINGULUS TECHNOLOGIES
BRIEF published on 04/04/2024 at 10:11, 7 months 17 days ago SINGULUS TECHNOLOGIES AG Announces Unqualified Audit for 2023 Financial Statements 2023 Annual Financial Statements Transparency SINGULUS TECHNOLOGIES Unqualified Audit
PRESS RELEASE published on 04/04/2024 at 10:06, 7 months 17 days ago EQS-Adhoc: SINGULUS TECHNOLOGIES AG: Adoption of the annual financial statements 2023 - Unqualified audit opinion SINGULUS TECHNOLOGIES AG approves adoption of the annual financial statements 2023 with an unqualified audit opinion. Details on the company's website soon 2023 Annual Financial Statements Singulus Technologies AG Unqualified Audit Opinion Adoption
PRESS RELEASE published on 02/08/2024 at 09:01, 9 months 13 days ago Original-Research: Singulus Technologies AG (von NuWays AG): HOLD Singulus Technologies AG receives a HOLD recommendation from NuWays AG with a target price of 1.60. The company looks ahead to a more promising FY24e despite a challenging FY23. Find out more in the full analysis HOLD Recommendation NuWays AG Target Price Singulus Technologies AG FY24e Outlook
Published on 11/21/2024 at 14:15, 14 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 29 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 29 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 29 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 12 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 14 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 53 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 31 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 9 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 44 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 44 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
